Channels
Caption
The AGSAA and Boehringer Ingelheim are proud to announce a new partnership aimed at better understanding the patient perspective in Aicardi-Goutieres Syndrome (AGS) and incorporating patient needs and desires into trial design. By combining their efforts, the partnership seeks to ensure that clinical trials for AGS are measuring what truly matters and are accurately assessing the effectiveness of potential treatments.
Read more at https://agsaa.org/news